Journal: NPJ Vaccines

Article Title: Repurposing anti-viral subunit and mRNA vaccines T cell immunity for intratumoral immunotherapy against solid tumors

doi: 10.1038/s41541-025-01131-y

Figure Lengend Snippet: Experimental design: C57BL/6 mice were prime-boost immunized intramuscularly with the HPV vaccine or unimmunized prior to TC-1 tumor subcutaneous challenge one week after boost. When tumor reached a volume between 50 and 100 m 3 , mice were treated six times with saline, HPV-vax alone (1/25 th of the human dose) or L1 165-173 peptide (0.5 μg) admixed with polyI:C LMW (50 μg). Mice were monitored twice a week for ( A , C ) tumor growth and (B, D) survival. A , C Tumor growth is shown as the mean of tumor volume for each group and SE ( n = 6–9 per group). Statistical analysis with Dunn’s test was performed for multiple comparison of tumor growth. B , D Survival comparisons were assessed by Mantel–Cox test (**** P < 0.0001, *** P < 0.001, ** P < 0.01 * P < 0.05 n.s.: not significant). E IFN-γ production was assessed after IT treatment by intracellular staining of circulating CD8 + T cells after in vitro restimulation with L1 165-173 peptide. Data are shown as individual values and mean of cytokine production of CD44 + CD8 + T cells with SE. F Circulating anti-tumor E7-specific CD8 + T cell responses were measured by dextramer staining after IT treatment. Data are shown as individual percentage and mean of H2-D b /E7 49-57 + CD44 + CD8 + T cells. G anti-HPV16 L1 VLP antibody responses were measured by ELISA in plasma samples. Data are shown as individual and geometric mean of IgG EC50 titer and 95% confidence interval. H Cytokine and chemokine production was measured using a bead-based multiplex immunoassay in tumor lysates. Heatmap shows the average Z-score of the amount of each analyte per 50 μg of protein. I – L The cellular infiltrate was assessed by flow cytometry. Data are shown as individual values and mean percentage within CD45 + cells of ( I ) activated CD8 + T cells defined as CD8 + CD44 + CD62L - PD1 + , ( J ) myeloid cells defined as CD11b + , and percent within CD11b + cells of ( K ) neutrophils defined as CD11b + Ly6G + Ly6C int and ( L ) macrophages defined as CD11b + F480 + Ly6G - Ly6C int . Data are shown as individual values and mean percentage of cells within indicated gated population and SE. Statistical analysis (* P < 0.05 or numeric values) was performed using Dunn’s test for multiple comparison between groups ( n = 4–5 per group).

Article Snippet: Mice were injected with 200 μg of an anti-mouse CD8 antibody (clone 2.43, BioXcell InVivoPlus) or a rat IgG2b control antibody (clone LTF-2, BioXcell InVivoPlus) diluted in 200 μl phosphate-buffered saline (PBS) on day 3 and 1 prior to the first IT injection and on day 1 prior to each subsequent IT injection.

Techniques: Saline, Comparison, Staining, In Vitro, Enzyme-linked Immunosorbent Assay, Clinical Proteomics, Multiplex Assay, Flow Cytometry

Journal: NPJ Vaccines

Article Title: Repurposing anti-viral subunit and mRNA vaccines T cell immunity for intratumoral immunotherapy against solid tumors

doi: 10.1038/s41541-025-01131-y

Figure Lengend Snippet: Experimental design: C57BL/6 mice were prime-boost immunized intramuscularly with the VZV vaccine prior to TC-1 tumor subcutaneous challenge one week after boost. When tumor reached a volume between 50 and 100 m , mice were treated six times with saline, VZV-vax alone (1/40 th of the human dose) or the MHC-II-restricted gE 71-90 peptide (2 μg) admixed with polyI:C LMW (50 μg). Mice were monitored twice a week for ( A ) tumor growth and ( B ) survival. A Tumor growth is shown as the mean of tumor volume for each group and SE ( n = 7 per group). Statistical analysis with Dunn’s test was performed for multiple comparison of tumor growth. B Survival comparisons were assessed by Mantel–Cox test (** P < 0.01, * P < 0.05). C Tumor-free mice from the VZV-vax and gE 71-90 + polyI:C-treated groups, and naïve mice were rechallenged with TC-1 cells, 60 days after the primary challenge and tumor growth was monitored twice a week until endpoint. D anti-VZV gE protein responses were measured by ELISA in plasma samples. Data are shown as individual values and geometric mean of the EC50 of IgG titer and 95% confidence interval. In a separate experiment, ( E ) IFN-γ, ( F ) TNF-α and ( G ) IL-2 production was assessed 36 h after the last IT treatment by intracellular staining of circulating CD4 + T cells after in vitro restimulation with VZV gE overlapping peptide library. Individual cytokine production is shown as individual values and mean percentage within CD44 + CD4 + T cells with SE. Statistical analysis was performed using Dunn’s test for multiple comparison between groups (* P < 0.05 ** P < 0.01, *** P < 0.001, **** P < 0.0001, numeric values, ns = not significant) ( n = 4 per group).

Article Snippet: Mice were injected with 200 μg of an anti-mouse CD8 antibody (clone 2.43, BioXcell InVivoPlus) or a rat IgG2b control antibody (clone LTF-2, BioXcell InVivoPlus) diluted in 200 μl phosphate-buffered saline (PBS) on day 3 and 1 prior to the first IT injection and on day 1 prior to each subsequent IT injection.

Techniques: Saline, Comparison, Enzyme-linked Immunosorbent Assay, Clinical Proteomics, Staining, In Vitro

Journal: Laboratory investigation; a journal of technical methods and pathology

Article Title: Establishment of a mouse model of enalapril-induced liver injury and investigation of the pathogenesis.

doi: 10.1038/labinvest.2017.22

Figure Lengend Snippet: Figure 7 Effects of neutrophil depletion on ELP-induced liver injury. An anti-Gr-1 monoclonal antibody was intraperitoneally administered to mice 36 h before ELP administration. The numbers of neutrophils in blood (a) and plasma ALT levels (b) at 6 h after ELP administration. The data are presented as the means ± s.e.m. (n = 4–6 mice per each group). The differences compared with the DEX/BSO-treated group were considered significant at **Po0.01 and ***Po0.001 and the differences between the DEX/BSO/ELP/Isotype IgG2b control-treated group and DEX/BSO/ELP/Anti-Gr-1-treated group were considered significant at #Po0.05 and ##Po0.01. ALT, alanine aminotransferase; BSO, L-buthionine-(S,R)-sulfoximine; DEX, dexamethasone; ELP, enalapril.

Article Snippet: Rat anti-mouse Gr-1 (RB6-8C5) monoclonal antibody (mAb) and rat IgG2b isotype control were purchased from TONBO Biosciences (San Diego, CA, USA).

Techniques: Clinical Proteomics, Control

Journal: bioRxiv

Article Title: Dynamic Regulation of CD300b, and CD300f on Myeloid Cells in Oral Immunotherapy

doi: 10.64898/2026.01.28.702205

Figure Lengend Snippet: Reduction in allergen-specific IgE from baseline to maintenance correlates with decreased CD300b expression on monocytes (A) and eosinophils (B). Higher CD300f expression on eosinophils correlates with greater IgE reduction (C), while increased CD300f expression on neutrophils correlates with increased allergen-specific IgG4 levels (D). Associations were assessed using Spearman’s rank correlation n=19.

Article Snippet: Isotype controls including Rat IgG2A and Rat IgG2B were obtained from R&D Systems, Minneapolis, MN.

Techniques: Expressing